Rep. Gottheimer Urges Gilead to Expand Access to Investigational COVID-19 Treatment for Patients With Severe Symptoms
March 30, 2020
March 30, 2020
GLEN ROCK, New Jersey, March 30 -- Rep. Josh Gottheimer, D-New Jersey, issued the following statement:
"Gilead Sciences is continuing to deny access of its investigational COVID-19 drug remdesivir to some patients suffering from extreme symptoms of the disease -- including some patients in North Jersey, like 34-year-old Bergenfield resident and father of two, Michael Goldsmith, who is currently suffering from extreme COVID-19 complications and fighting for his life.
"Gilead Sciences is continuing to deny access of its investigational COVID-19 drug remdesivir to some patients suffering from extreme symptoms of the disease -- including some patients in North Jersey, like 34-year-old Bergenfield resident and father of two, Michael Goldsmith, who is currently suffering from extreme COVID-19 complications and fighting for his life.